Interferon β1a and depression in secondary progressive MS: Data from the SPECTRIMS trial

Neurology

Volumn 59, Issue 5, 2002, Pages 744-746

  Patten, Scott B ^a   Metz, Luanne M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCORING SYSTEM; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

EID: 0037055958     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.5.744     Document Type: Article

References (9)

1. Klapper JA. Interferon beta treatment of multiple sclerosis. Neurology 1994;44:188.
2. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
4. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
5. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure 1977;1:385-401.
6. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979;9:139-145.
7. Beck AT, Steer RA, Kovacs M, et al. Hopelessness and eventual suicide: a 10 year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry 1985;142:559-563.
8. McDowell I, Newell C. Measuring health, a guide to rating scales and questionnaires, 2nd ed. New York: Oxford University Press, 1996.
9. Jacobs LD, Beck RY, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.